Vasopressor agents in shock.
D001921:Brain / Q000098:blood supply; D002560:Cerebrovascular Circulation / Q000187:drug effects; D006801:Humans; D008680:Metaraminol / Q000627:therapeutic use; D009020:Morphine / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000188:drug therapy; D009269:Nalorphine / Q000494:pharmacology; D009638:Norepinephrine / Q000008:administration & dosage / Q000627:therapeutic use; D012769:Shock / Q000188:drug therapy* / Q000503:physiopathology; D012770:Shock, Cardiogenic / Q000188:drug therapy; D012771:Shock, Hemorrhagic / Q000188:drug therapy; D012772:Shock, Septic / Q000188:drug therapy; D014662:Vasoconstrictor Agents / Q000627:therapeutic use*
D014662:Vasoconstrictor Agents; D009020:Morphine; D008680:Metaraminol; D009269:Nalorphine; D009638:Norepinephrine